Archive | Cancer in the News

Once Monthly Opdivo Use Approved in EU for Certain Melanoma, Renal Cell Cancer Patients

The European Commission has approved a new dosing schedule for Opdivo(nivolumab), allowing the PD-1 inhibitor to be given every four weeks to patients with advanced melanoma and those with previously treated renal cell carcinoma.

Read the full story

Posted in Melanoma In The News, European Approval

FDA approves Tafinlar-Mekinist combination for adjuvant treatment of BRAF-mutant melanoma

The FDA approved the combination of dabrafenib and trametinib for adjuvant treatment of patients with BRAF V600E- or BRAF V600K-positive melanoma that has spread to their lymph nodes.

Read the full story

Posted in Melanoma In The News, FDA

Europe Approves New Nivolumab Dosing Schedules

A 4-week dosing schedule for nivolumab (Opdivo) has been approved by the European Commission for the treatment of patients with advanced melanoma and previously treated renal cell carcinoma (RCC), Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor, has announced.

Read the full story

Posted in Melanoma In The News, European Approval

Melanoma: FDA Approves Adjuvant Dabrafenib With Trametinib

The US Food and Drug Administration (FDA) approved dabrafenib with trametinib as an adjuvant therapy following complete resection for patients with BRAFV600E- or V600K-mutated melanoma with lymph node involvement, according to a press release.1

Read the full story

Posted in Melanoma In The News, FDA

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories